2+ , the second most prevalent trace element in the body, is essential for supporting a wide range of biological functions. While the majority of Zn 2+ in the brain is protein-bound, a significant proportion of free Zn 2+ is found co-localized with glutamate in synaptic vesicles and is released in an activity-dependent manner. Clinical studies have shown Zn 2+ levels are significantly lower in blood and cerebrospinal fluid of children that suffer febrile seizures. Likewise, investigations in multiple animal models demonstrate that low levels of brain Zn 2+ increase seizure susceptibility. Recent work provides human genetic evidence that disruption of brain Zn 2+ homeostasis at the level of the synapse is associated with increased seizure susceptibility. In this review, we have explored the clinical, functional and genetic data supporting the view that low synaptic Zn 2+ increases cellular excitability and febrile seizure susceptibility. Finally, the review focuses on the potential of therapeutic Zn 2+ supplementation for at risk patients.
Zn
2+ is an essential element that supports a variety of biological functions throughout the body. It plays a critical role as a cofactor to stabilize proteins structurally and to catalyse a variety of key enzymatic reactions. Secondly, it is present as a free ion in glutamatergic vesicles and participates in synaptic transmission. Zn 2+ is regionally augmented in the brain with high levels seen in the hippocampus, neocortex, amygdala and striatum (Frederickson, 1989; Frederickson et al., 2005) . There is an abundance of evidence indicating the potential role of free Zn 2+ in the pathogenesis of several neurological diseases including Parkinson's (Stelmashook et al., 2014 ) and Alzheimer's disease (Baaj et al., 2009 ) that will not be covered here. Instead, we focus on the impact of free Zn 2+ in the context of seizures.
Zn 2+ and epilepsy
Epilepsy encompasses a broad range of seizure disorders differentiated by brain location, electroencephalogram signatures, clinical presentation and time of onset (Berg et al., 2010) . Several studies have implicated changes in Zn 2+ homeostasis in the underlying pathology of epilepsy (Marger et al., 2014) . However, Zn 2+ seems to play a variety of roles in setting seizure susceptibility with both pro-and anticonvulsant effects reported. For example, a recent metaanalysis concluded that serum Zn 2+ concentration is significantly higher in non-medicated patients with epilepsy (Saghazadeh et al., 2015) . However, others suggest that Zn 2+ levels are significantly lower in the serum of children with refractory epilepsy (Kheradmand et al., 2014; Saad et al., 2014) . This mixed picture is likely to reflect the multiple biological roles of Zn 2+ . The impact of altered Zn 2+ levels will also depend on the brain region affected and developmental time windows during which seizures occur.
In this review, we have specifically explored the role of Zn 2+ in febrile seizures (FS). For this seizure syndrome, there is good evidence that Zn 2+ is low in both the serum and cerebrospinal fluid of individuals with FS as compared with those with either fever or seizures alone (Burhanoglu et al., 1996; Amiri et al., 2010; Ganesh et al., 2011; Lee and Kim, 2012; Saghazadeh et al., 2015) . We present clinical, physiological and genetic data that demonstrate how a disruption in Zn
2+
homeostasis could contribute to FS susceptibility.
Febrile seizures
FS are the most common seizure syndrome, affecting approximately 3% of all children. It is typically a selflimiting disorder where a child under the age of 5 has seizures only in response to fever (Verity et al., 1985) . However, FS are a major health problem accounting for 1 in 200 paediatric emergency department (ED) admissions (Martindale et al., 2011) . Although often considered benign, FS can result in short-term physical, psychological and behavioural problems in children and parents. Worse still, they can be the harbinger of various forms of epilepsy in later life with long-term studies showing that 7% of children with FS subsequently develop epilepsy (Annegers et al., 1987) . Despite their significant clinical burden, little progress in understanding the mechanistic causes of FS has been made over the last decade, making this area a key future research priority for the epilepsy field (Helbig and Lowenstein, 2013) .
Zn 2+ levels and FS
Several clinical studies report low total Zn 2+ levels in the blood of children who have been diagnosed with FS (Burhanoglu et al., 1996; Amiri et al., 2010; Ganesh et al., 2011; Lee and Kim, 2012) . Meta-analyses confirm that the concentration of serum Zn 2+ in FS patients is significantly lower than in children with central nervous system infections, meningismus, encephalitis, febrile illness without seizure, afebrile seizure or no illness (Saghazadeh et al., 2015) . Direct Zn 2+ levels in serum may not always correlate with brain cerebrospinal fluid levels (Palm and Hallmans, 1982) , in part due to the fact that uptake across the blood-brain barrier is mediated through active transport (Grabrucker et al., 2011 These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 ( a,b,c Alexander et al., 2015a,b,c) .
cerebrospinal fluid Zn 2+ levels in FS patients and found them to be significantly reduced, more specifically implicating brain Zn 2+ levels (Burhanoglu et al., 1996) deficiency is common (Burhanoglu et al., 1996; Amiri et al., 2010; Ganesh et al., 2011; Saghazadeh et al., 2015) . Thus, in these settings, low Zn 2+ levels may be simply linked to nutritional deficiency. are lower in FS patients with normal diet intake, there is an emerging and strengthening relationship between elevated serum markers of inflammation and Zn 2+ deficiency (Murr et al., 2012; Jung et al., 2015; Ghashut et al., 2016) . Furthermore, in a pig model of peritonitis, serum Zn 2+ levels drop by half 2 h post-infection and over 75% by 6 h, with free Zn 2+ also falling (Hoeger et al., 2015) . Acute sepsis or severe malaria are also associated with low serum Zn 2+ , and these levels correlate with changes in inflammatory markers (Hoeger et al., 2015; Ghashut et al., 2016) . Zn 2+ is essential for the execution and regulation of both innate and humoral immune responses, primarily through its capacity to act as a structural and/or catalytic protein cofactor (Rink and Haase, 2007) . Within hours of pathogen detection or trauma, inflammatory cytokines like TNF trigger the rapid sequestration of free Zn 2+ from the serum to serve these functions (Cousins and Leinart, 1988) . Intracellular Zn 2+ quickly works as part of a negative feedback loop to extinguish the inflammatory response and restore Zn 2+ homeostasis (Liu et al., 2013) , but in some cases, inflammatory hypozincaemia can persist for days or weeks and is associated with a worse prognosis in patients suffering severe forms of systemic inflammation like sepsis (Wong et al., 2007 (Cole et al., 1999) .
This Zn 2+ is released in an activity-dependent manner resulting in concentrations as high as 100-300 μM in the extracellular space (Vogt et al., 2000; Qian and Noebels, 2005; Pan et al., 2011; Vergnano et al., 2014) . Synaptic Zn 2+ is present primarily in cortical and limbic structures and is enriched in the hippocampus (Frederickson et al., 2005) , a brain region frequently implicated in FS (Dube et al., 2006; Wimmer et al., 2010) . A mouse ZnT3 gene knockout strain exhibits increased susceptibility to pro-convulsant drug-induced seizures (Cole et al., 2000) . Our own work demonstrated an increased susceptibility of ZnT3 null mice to FS (Hildebrand et al., 2015) ; we used environmental heat to increase core body temperature and trigger thermogenic seizures (Reid et al., 2013; Richards et al., 2013) . Collectively, these data implicate low synaptic Zn 2+ as a susceptibility factor in FS.
Genetic susceptibility, synaptic Zn 2+ and FS Genetic factors play an important role in susceptibility to FS. About 25% of patients with FS have a family history of FS (Kjeldsen et al., 2002) , and monozygotic twins have a higher concordance for FS than dizygotic twins (Eckhaus et al., 2013) . Based on the central role of synaptic Zn 2+ in modulating excitability and clinical evidence implicating low cerebrospinal fluid and blood levels of Zn 2+ in FS, we took a candidate gene approach and screened SLC30A3 that encodes ZnT3 in a population who have suffered from FS (Hildebrand et al., 2015) . The screen revealed a heterozygous variant (c.892C > T; p.R298C) that was enriched in FS populations from Australia and Europe but absent from population-matched controls. The variant is reported at over 10-fold lower frequency on the Exome Aggregation Database with a case-control analysis giving an odds ratio of about 11 (Hildebrand et al., 2015) . Given a lifetime prevalence of 2-3%, the 10-fold increase in risk would lead to an absolute risk of over 1 in 5 of developing FS for a patient harbouring the variant. Functional analysis of the variant demonstrated a loss-of-function due to a trafficking deficit (Hildebrand et al., 2015) . Taken together, the genetic, clinical and experimental animal data we have outlined here support the idea that a loss of synaptic Zn 2+ is likely to increase the susceptibility of an individual to FS.
Low synaptic Zn 2+ and neuronal excitability
Multiple potential mechanisms may underlie increased neuronal excitability under conditions of low synaptic Zn 2+ because extracellular Zn 2+ interacts with a range of ion channels, receptors and transporters (Marger et al., 2014) . In particular, Zn 2+ directly inhibits a number of ionotropic receptors commonly found at central synapses (Paoletti et al., 2009) . These include GABA A , AMPA and NMDA receptors. Zn 2+ block of GABA A receptors has been implicated in the underlying pathogenesis of epilepsy (Buhl et al., 1996) ; here, block of GABA A receptors are proposed to result in reduced neuronal network inhibition. Zn 2+ has also been shown to inhibit astrocyte glutamate uptake potentially increasing the activation of both AMPA and NMDA receptors (Suh et al., 2007; Carver et al., 2016) . However, as presented above, FS are associated with reductions in Zn 2+ levels, which might be expected to lead to increased GABA A -mediated transmission and increased glutamate uptake, and therefore, these proposed mechanisms seem to be unlikely contributors to increased excitability. AMPA and NMDA receptors are localized in the postsynaptic density of glutamatergic synapses and are, therefore, well positioned to be modulated by synaptic Zn 2+ . The role of AMPA receptors in driving excitability Zn 2+ is unclear given the conflicting evidence as to whether endogenously released synaptic Zn 2+ modulates these receptors (Vergnano et al., 2014; Kalappa et al., 2015) . NMDA receptors stand out as a target for Zn 2+ because of their high sensitivity, with levels as low as 10 nM causing significant inhibition (Chen et al., 1997; Paoletti et al., 1997; Traynelis et al., 1998) . Furthermore, Vergnano and colleagues demonstrate that activity-dependent release of Zn 2+ at hippocampal synapses modulates NMDA-mediated excitability (Vergnano et al., 2014) . This impact on excitability is limited to higher stimulation frequencies, a situation likely to occur during neuronal hyperexcitability induced by high brain temperatures (Mizunuma et al., 2009 ). Vergnano and colleagues also show that trains of NMDA receptor-mediated synaptic events are significantly larger in ZnT3 null mice. As discussed above, ZnT3 knockout mice are more sensitive to heat-induced seizures that model FS (Hildebrand et al., 2015) . A variety of mechanistic models could explain this increased excitability. However, a model where heat-mediated increases in hippocampal neuronal excitability cannot be constrained when synaptic Zn 2+ levels are too low to modulate NMDA receptor activity provides a simple solution to explain increased susceptibility to FS (Figure 1 ).
Therapeutic interventions
The possibility of recurrence of FS is high with approximately one-third of patients having a second occurrence (Annegers et al., 1990) . Reducing this risk in children would have significant clinical and economic implications since FS accounts for over 1 in 200 paediatric emergency department (ED) admissions (Martindale et al., 2011) . Moreover, there is some evidence that long FS may result in hippocampal damage and later epilepsy (Annegers et al., 1987) , so prevention of FS recurrence might reduce the frequency of later epilepsy. However, given the often self-limiting nature of FS, it is imperative that any therapeutic intervention is safe and well tolerated. An obvious therapeutic option is to give Zn 2+ as a supplement to FS patients who are shown to be deficient in Zn 2+ . Zn 2+ can be given orally as Zn 2+ acetate, which is the most commonly administered and well-tolerated form of Zn 2+ . In support this idea, it has been found that Zn 2+ supplementation can be protective in the hyperthermia-induced model of FS in rats (Aydin et al., 2016) . However, one overriding concern for this approach is how effective it is in increasing brain levels of Zn 2+ quickly. This is because the uptake of Zn 2+ across the blood-brain barrier is mediated through active transport and is highly regulated (Grabrucker et al., 2011) . This may limit the effectiveness of Zn 2+ supplementation in FS since higher brain levels are likely to be required to be protective. Alternative mechanisms of increasing Zn 2+ brain levels rapidly need to be considered. One example is the development of Zn 2+ -loaded nanoparticles that may facilitate the delivery of Zn 2+ to the brain (Chhabra et al., 2015) . Facilitating Zn 2+ uptake by enhancing transport into the brain and (Qin et al., 2009; Qian et al., 2011) and are therefore good potential molecular targets. Furthermore, given the proposed importance of synaptic Zn 2+ in the underlying mechanism of FS, agents that increase the activity of ZnT3 may be worth investigating. This could be either through direct activation or through secondary molecular targets. For example, Zn 2+ transport activity by ZnT3 in neuronal cells can be potentiated by the overexpression of the ClC-3 chloride channel (Salazar et al., 2004) .
Future directions
The evidence associating low levels of Zn 2+ in serum and cere- (ZnT1), SLC39A1 (ZIP1) and SLC39A3 (ZIP3) are good candidates given their role in controlling Zn 2+ flux in neurons (Qin et al., 2009; Qian et al., 2011) . Other gene candidates involved in Zn 2+ -related mediation of downstream excitability include the GluN2B and GluN2A receptor subunits encoded by GRIN2A and GRIN2B respectively. Interestingly, genetic studies in epilepsy have identified mutations in NMDA receptors that alter Zn 2+ sensitivity (Lesca et al., 2013; Yuan et al., 2014) , although both decreases and increases have been observed (Lesca et al., 2013; Yuan et al., 2014; Serraz et al., 2016) .
Conclusions
FS has a significant clinical and economic impact with few proven preventative or therapeutic strategies currently available in the clinic. The evidence associating low levels of Zn 2+ in serum and cerebrospinal fluid to increased risk of FS is strong (Saghazadeh et al., 2015) . The increased susceptibility of the ZnT3 null mouse to thermogenic seizures and the enhancement of a loss-of-function ZnT3 variants in FS patients directly link a reduction in synaptic Zn 2+ to susceptibility to FS (Hildebrand et al., 2015) . Data presented here support the idea that restoring synaptic Zn 2+ concentrations is a potential therapeutic strategy that is simple and inexpensive. Future research is required to test this hypothesis both at the preclinical and clinical level.
